Michael Wald is a collaborative scientific and technical expert in drug development, currently serving as a Development Asset Leader at Biogen since 2023. With extensive experience in R&D across major biopharma companies, Michael has led Phase II and Phase III programs while working closely with key opinion leaders and executive leadership. Previously, Michael held various roles, including Scientific Director for Biomarkers at Biogen and Imaging Expert at Novartis Institutes for BioMedical Research. Michael earned a PhD in Bioengineering from the University of Pennsylvania and is currently pursuing a BS at Boston College.
This person is not in the org chart
This person is not in any teams
This person is not in any offices